{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:31:44Z","timestamp":1777984304045,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12724-w","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T11:16:23Z","timestamp":1770203783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disproportionality analysis and \u201cperpetrator\u201d or \u201caccomplice\u201d review of Baloxavir marboxil in public FAERS database"],"prefix":"10.1186","volume":"26","author":[{"given":"Fang","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"10095","key":"12724_CR1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0140-6736(17)30129-0","volume":"390","author":"C Paules","year":"2017","unstructured":"Paules C, Subbarao K, Influenza. Lancet. 2017;390(10095):697\u2013708.","journal-title":"Lancet"},{"issue":"10127","key":"12724_CR2","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","volume":"391","author":"AD Iuliano","year":"2018","unstructured":"Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285\u2013300.","journal-title":"Lancet"},{"key":"12724_CR3","unstructured":"World health organization. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza. Accessed 01 Jul 2025."},{"key":"12724_CR4","doi-asserted-by":"crossref","unstructured":"Dufrasne F. Baloxavir marboxil: an original new drug against influenza. Pharmaceuticals (Basel). 2021;15(1).","DOI":"10.3390\/ph15010028"},{"key":"12724_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","volume":"160","author":"T Noshi","year":"2018","unstructured":"Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, et al. In vitro characterization of Baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. 2018;160:109\u201317.","journal-title":"Antiviral Res"},{"key":"12724_CR6","doi-asserted-by":"crossref","unstructured":"Takashita E. Influenza polymerase inhibitors: mechanisms of action and resistance. Cold Spring Harb Perspect Med. 2021;11(5).","DOI":"10.1101\/cshperspect.a038687"},{"issue":"5","key":"12724_CR7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jmii.2021.04.002","volume":"54","author":"YC Kuo","year":"2021","unstructured":"Kuo YC, Lai CC, Wang YH, Chen CH, Wang CY. Clinical efficacy and safety of Baloxavir Marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials. J Microbiol Immunol Infect. 2021;54(5):865\u201375.","journal-title":"J Microbiol Immunol Infect"},{"issue":"7","key":"12724_CR8","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/17512433.2021.1917378","volume":"14","author":"S Tejada","year":"2021","unstructured":"Tejada S, Tejo AM, Pe\u00f1a-L\u00f3pez Y, Forero CG, Corbella X, Rello J. Neuraminidase inhibitors and single dose Baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14(7):901\u201318.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"12724_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/03007995.2020.1839400","volume":"37","author":"V Taieb","year":"2021","unstructured":"Taieb V, Ikeoka H, Wojciechowski P, Jablonska K, Aballea S, Hill M, et al. Efficacy and safety of Baloxavir Marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a bayesian network meta-analysis. Curr Med Res Opin. 2021;37(2):225\u201344.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"12724_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/INF.0000000000004062","volume":"42","author":"JB Baker","year":"2023","unstructured":"Baker JB, Block SL, Cagas SE, Macutkiewicz LB, Collins C, Sadeghi M, et al. Safety and efficacy of Baloxavir Marboxil in Influenza-infected children 5\u201311 years of age: A post hoc analysis of a phase 3 study. Pediatr Infect Dis J. 2023;42(11):983\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"12724_CR11","doi-asserted-by":"publisher","first-page":"1439115","DOI":"10.3389\/fphar.2024.1439115","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang Y, Wei S, Tian H, Cheng J, Zhong Y, Zhong X, et al. Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023. Front Pharmacol. 2024;15:1439115.","journal-title":"Front Pharmacol"},{"issue":"1","key":"12724_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13023-024-03294-8","volume":"19","author":"Q Wang","year":"2024","unstructured":"Wang Q, Zhuang JL, Han B, Chen M, Zhao B. Drug-associated porphyria: a pharmacovigilance study. Orphanet J Rare Dis. 2024;19(1):286.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"12724_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12888-020-02711-z","volume":"20","author":"A Revet","year":"2020","unstructured":"Revet A, Montastruc F, Roussin A, Raynaud JP, Lapeyre-Mestre M, Nguyen TTH. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry. 2020;20(1):308.","journal-title":"BMC Psychiatry"},{"key":"12724_CR14","doi-asserted-by":"publisher","first-page":"1333662","DOI":"10.3389\/fphar.2024.1333662","volume":"15","author":"B Zhao","year":"2024","unstructured":"Zhao B, Fu Y, Cui S, Chen X, Liu S, Luo L. A real-world disproportionality analysis of everolimus: data mining of the public version of FDA adverse event reporting system. Front Pharmacol. 2024;15:1333662.","journal-title":"Front Pharmacol"},{"issue":"4","key":"12724_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.7150\/ijms.8.332","volume":"8","author":"T Sakaeda","year":"2011","unstructured":"Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, et al. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci. 2011;8(4):332\u20138.","journal-title":"Int J Med Sci"},{"issue":"5","key":"12724_CR16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","volume":"37","author":"C Michel","year":"2017","unstructured":"Michel C, Scosyrev E, Petrin M, Schmouder R. Can disproportionality analysis of Post-marketing case reports be used for comparison of drug safety profiles? Clin Drug Investig. 2017;37(5):415\u201322.","journal-title":"Clin Drug Investig"},{"issue":"7","key":"12724_CR17","doi-asserted-by":"publisher","first-page":"e14862","DOI":"10.1111\/cns.14862","volume":"30","author":"Z Xiao","year":"2024","unstructured":"Xiao Z, Cao J, Wu S, Zhou T, Li C, Duan J, et al. Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4\/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system. CNS Neurosci Ther. 2024;30(7):e14862.","journal-title":"CNS Neurosci Ther"},{"issue":"6","key":"12724_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40264-013-0032-z","volume":"36","author":"E Poluzzi","year":"2013","unstructured":"Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, et al. Antipsychotics and Torsadogenic risk: signals emerging from the US FDA adverse event reporting system database. Drug Saf. 2013;36(6):467\u201379.","journal-title":"Drug Saf"},{"issue":"7","key":"12724_CR19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803.","journal-title":"Int J Med Sci"},{"issue":"6","key":"12724_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of A disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47(6):585\u201399.","journal-title":"Drug Saf"},{"issue":"6","key":"12724_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement. Drug Saf. 2024;47(6):575\u201384.","journal-title":"Drug Saf"},{"key":"12724_CR22","doi-asserted-by":"crossref","unstructured":"Kumar A, editor. Signal analysis in pharmacovigilance: principles and processes. CRC. 2024;137\u201342.","DOI":"10.1201\/9781032629940"},{"key":"12724_CR23","doi-asserted-by":"crossref","unstructured":"Kumar A, editor. Signal analysis in pharmacovigilance: principles and processes. CRC. 2024; 73\u201389.","DOI":"10.1201\/9781032629940"},{"issue":"1","key":"12724_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1186\/s12879-024-09339-4","volume":"24","author":"Y Li","year":"2024","unstructured":"Li Y, Wang X, Liao Y, Zeng Y, Lin W, Zhuang W. Safety analysis of oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system. BMC Infect Dis. 2024;24(1):446.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"12724_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.24920\/003663","volume":"35","author":"Y Ju","year":"2020","unstructured":"Ju Y, Qiao H, Zhang Y, Li Y. Three cases of rhabdomyolysis induced by viral infections in children and literature review. Chin Med Sci J. 2020;35(4):383\u20136.","journal-title":"Chin Med Sci J"},{"issue":"8","key":"12724_CR26","doi-asserted-by":"publisher","first-page":"101015","DOI":"10.1016\/j.disamonth.2020.101015","volume":"66","author":"BMI Cabral","year":"2020","unstructured":"Cabral BMI, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis Dis Mon. 2020;66(8):101015.","journal-title":"Rhabdomyolysis Dis Mon"},{"key":"12724_CR27","doi-asserted-by":"crossref","unstructured":"Runnstrom M, Ebied AM, Khoury AP, Reddy R. Influenza-induced rhabdomyolysis. BMJ Case Rep. 2018;11(1).","DOI":"10.1136\/bcr-2018-226610"},{"key":"12724_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.18433\/jpps31375","volume":"24","author":"K Kurosawa","year":"2021","unstructured":"Kurosawa K, Takasaki S, Suzuki H, Sato Y, Akiyama M, Akiba M, et al. A case of an increase in prothrombin Time-International normalized ratio by interaction between warfarin and Baloxavir Marboxil in a patient on implantable ventricular assist device. J Pharm Pharm Sci. 2021;24:37\u201340.","journal-title":"J Pharm Pharm Sci"},{"key":"12724_CR29","unstructured":"The UMC measures of disproportionate reporting. Available online: https:\/\/www.who-umc.org\/media\/164041\/measures-of-disproportionate-reporting_2016.pdf. Accessed 6 Oct 2024."},{"issue":"8","key":"12724_CR30","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40264-020-00939-y","volume":"43","author":"S Hult","year":"2020","unstructured":"Hult S, Sartori D, Bergvall T, Hedfors Vidlin S, Grundmark B, Ellenius J, et al. A feasibility study of Drug-Drug interaction signal detection in regular pharmacovigilance. Drug Saf. 2020;43(8):775\u201385.","journal-title":"Drug Saf"},{"key":"12724_CR31","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3389\/fphar.2019.01319","volume":"10","author":"Y Noguchi","year":"2019","unstructured":"Noguchi Y, Tachi T, Teramachi H. Review of statistical methodologies for detecting Drug-Drug interactions using spontaneous reporting systems. Front Pharmacol. 2019;10:1319.","journal-title":"Front Pharmacol"},{"issue":"6","key":"12724_CR32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11886-023-01875-w","volume":"25","author":"CJ Ngwudike","year":"2023","unstructured":"Ngwudike CJ, Villalobos A. Correlation between cardiovascular protection and influenza vaccination. Curr Cardiol Rep. 2023;25(6):571\u20136.","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"12724_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/HCO.0000000000001018","volume":"38","author":"AC Mares","year":"2023","unstructured":"Mares AC, Mukherjee D. Influenza vaccination in mitigating vascular events and risk. Curr Opin Cardiol. 2023;38(4):327\u201330.","journal-title":"Curr Opin Cardiol"},{"issue":"1","key":"12724_CR34","doi-asserted-by":"publisher","first-page":"20235","DOI":"10.1038\/s41598-023-47690-9","volume":"13","author":"F Omidi","year":"2023","unstructured":"Omidi F, Zangiabadian M, Shahidi Bonjar AH, Nasiri MJ, Sarmastzadeh T. Influenza vaccination and major cardiovascular risk: a systematic review and meta-analysis of clinical trials studies. Sci Rep. 2023;13(1):20235.","journal-title":"Sci Rep"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12724-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12724-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12724-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:23:54Z","timestamp":1772796234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12724-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12724"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12724-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6884001\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study utilized publicly available and anonymized datasets, which do not require ethical approval under the Declaration of Helsinki guidelines. All data were accessed and analyzed in compliance with the original data providers \u2018terms of use\u2019.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"508"}}